Figure 1.

Treatment with eltanexor leads to alterations in apoptotic proteins, and combination with venetoclax synergizes to inhibit growth of AML cells in vitro. Western blot analysis of MV-4-11 and MOLM-13 cells after 24 hours of treatment with dimethyl sulfoxide (DMSO [D]) or a dose titration of eltanexor (ELTA) to determine protein levels of XPO1, p53, MCL1, and cleaved caspase 3. Actin was used as a loading control. Vertical line indicates different exposures because of varying levels of endogenous XPO1.